Oxandrolone Is Called “Mild.”
The Human Data Tell a Sharper Story.

Oxandrolone, commonly known by the former brand Anavar or Oxandrin, is an orally active anabolic-androgenic steroid. It binds the androgen receptor and shifts muscle protein turnover toward anabolism. Its structure makes it orally bioavailable and prevents aromatization into estrogen. Those features help explain the reputation for a “dry,” comparatively manageable oral anabolic.^[1][6]

Human studies support four defensible claims. Oxandrolone can stimulate net muscle protein synthesis over days; add lean tissue over weeks; increase measured muscle area and some strength outcomes; and counter profound catabolism after major burns or HIV-associated weight loss.^{[3][5][6][7][9][10][11]}

But the outcome depends on the starting problem. Preserving muscle in a child with burns over 30% of total body surface area is a major therapeutic success. Adding lean tissue to a functionally limited woman during supervised resistance training is encouraging. Neither directly estimates what a resistance-trained healthy adult would gain, retain or risk under a different exposure.

The nickname usually bundles several observations: oxandrolone does not aromatize, it was developed for oral use, and its historical anabolic-to-androgenic reputation looked favorable compared with some older agents. In practice that can mean less estrogen-mediated water retention and no direct aromatization-driven gynecomastia pathway. It does not mean “nonandrogenic.”

The archived label is explicit: complete separation of anabolic and androgenic effects has not been achieved. Exogenous anabolic androgens suppress pituitary luteinizing hormone; at larger exposures, spermatogenesis may also be suppressed through follicle-stimulating-hormone feedback. In women, androgenic changes can include voice deepening, hirsutism, acne, clitoral enlargement and menstrual disturbance; some virilizing changes may be irreversible even after discontinuation.^[1]

Oral convenience also has a chemical cost. Oxandrolone is a 17α-alkylated androgen, the design that helps it survive first-pass metabolism. The same class carries warnings for cholestatic hepatitis, peliosis hepatis and hepatic tumors. Absence of estrogen conversion does not protect HDL, LDL, the liver or endogenous hormone production.

The cleanest body-composition experiment randomized 32 healthy men aged 60–87 to 20 mg/day or placebo for 12 weeks. Oxandrolone increased lean body mass by 3.0 ± 1.5 kg, total body water by 2.9 ± 3.7 kg and proximal-thigh muscle area by 12.4 ± 8.4 cm². One-repetition-maximum strength increased 5.1% to 9.3% across four exercises, more than placebo. Total fat fell 1.9 ± 1.0 kg and trunk fat 1.3 ± 0.6 kg.^[3]

Those are real anabolic and body-composition effects. MRI thigh area and strength make “it was only water” untenable. Yet the water change was almost as large as the lean-mass change, and these were older men, not trained young lifters. Most importantly, 12 weeks after treatment ended, lean mass and strength were no longer different from baseline. Much of the fat reduction persisted.^[3]

A second unusually relevant trial put 29 functionally limited women, average age about 75, through high-intensity progressive resistance training three times weekly for 12 weeks. Adding 10 mg/day of oxandrolone produced 2.6 kg more whole-body lean-tissue gain than training with placebo, including significant advantages in arm, leg and trunk lean tissue. But strength, power, chair stand, balance and other functional improvements occurred with training and were not significantly better between groups.^[5]

This is a crucial separation: extra lean tissue on the scan did not yield extra function over a well-designed training program. The study is valuable because it actually combined the drug with resistance training, but the sample was small, older and functionally limited. It cannot establish either long-term safety or a bodybuilding effect in healthy women.

Major burns create a prolonged hypermetabolic state with extreme protein breakdown, weakness, growth disruption and bone loss. That is the setting in which a pharmacologic anabolic can solve a much larger problem than adding a few kilograms to an otherwise healthy body.

In 81 adults with burns covering 20%–60% of total body surface area, 10 mg every 12 hours reduced average hospital stay from 43.3 ± 5.3 days with placebo to 31.6 ± 3.1 days. The trial stopped at an interim analysis, which makes the result important but also more vulnerable to effect-size inflation than a fully completed target enrollment. Transaminase monitoring was part of the authors’ conclusion.^[9]

The pediatric program followed children with burns over 30% of body surface area. Seventy received 0.1 mg/kg twice daily for a year and 152 served as controls; exercise was separately randomized after discharge. Investigators reported lower resting energy expenditure and cardiac work, better height percentile and bone mineral content, and greater lean mass and muscle strength when treatment was combined with exercise. Benefits differed by age and the trial came from a highly specialized single-center program.^[10]

Shorter pediatric experiments also demonstrated improved net muscle protein balance. These findings show a drug acting against catastrophic hypercatabolism; they should not be reframed as proof that a healthy adult has the same benefit-risk ratio. A more recent randomized adult burn study and systematic reviews support a recovery signal while leaving heterogeneity in timing, populations and outcomes.^[11][13][14]

HIV-associated wasting tells a similarly contextual story. In 262 men with documented weight loss, all groups—including placebo—gained weight over 12 weeks. Mean gains were 1.1 kg with placebo and 1.8, 2.8 and 2.3 kg at 20, 40 and 80 mg/day. Body-cell mass rose in all groups. In a separate 24-man study, every participant received testosterone and supervised resistance training; adding 20 mg/day of oxandrolone produced larger lean-mass and strength gains, but also lowered HDL and led one participant to stop for elevated liver tests.^[7][8]

Oxandrolone has a better human evidence file than many performance compounds. The mistake is not believing it can build tissue. The mistake is flattening every endpoint into “muscle gain.”

• Net muscle protein synthesis proves an acute anabolic effect. It does not quantify months of hypertrophy.
• Lean mass includes muscle, water, glycogen, organs and connective tissue. It becomes more convincing when paired with MRI and strength.
• Muscle cross-sectional area is closer to hypertrophy, but still does not reveal fiber type, architecture or performance.
• Strength is meaningful but reflects neural learning, testing familiarity and starting function as well as tissue growth.
• Hospital stay or recovery can be clinically important without predicting an athlete’s result.

The older-men trial triangulated DXA, MRI, body water and 1RM, making it the strongest compact case that the anabolic effect was more than a measurement artifact. The older-women trial delivered the counterweight: more lean tissue did not amplify functional adaptations beyond training. The right conclusion is neither “fake gains” nor “guaranteed performance,” but a dose of intellectual discipline.

In the older-men trial, HDL cholesterol fell 0.49 ± 0.21 mmol/L—about 19 mg/dL—while directly measured LDL rose 0.57 ± 0.67 mmol/L, about 22 mg/dL. Non-HDL cholesterol also rose. The changes were largely reversible after treatment, but that does not make the exposure neutral while it is occurring.^[4]

The label warns that HDL reductions and LDL increases can be marked and may seriously affect atherosclerotic and coronary risk. It also warns about cholestatic hepatitis at relatively low dose, peliosis hepatis and liver-cell tumors with androgenic anabolic steroids. Short trials reporting tolerable liver tests cannot exclude uncommon or cumulative injury.^[1]

Suppression is not a technicality. An androgen that activates the receptor also feeds back on the hypothalamic-pituitary-gonadal axis. In men that can mean lower endogenous testosterone and impaired spermatogenesis; in women, virilizing effects can be consequential and sometimes irreversible. Pregnancy is contraindicated because of fetal masculinization risk. These facts do not become less relevant because the compound has been administered medically to women or children under controlled conditions.

Product identity adds another layer outside trials. The clinical studies used verified preparations, fixed protocols and active follow-up. An unapproved online product can contain the wrong dose, another steroid or contaminants. No efficacy trial validates that supply chain.

Oxandrin and several generic oxandrolone applications were withdrawn effective June 28, 2023. That history is sometimes summarized as a commercial discontinuation. FDA’s determination goes further: the agency concluded that the reference product was withdrawn for reasons of safety or effectiveness. A Federal Register correction published October 7, 2026 clarified that the listed generic applications referencing Oxandrin were also withdrawn for reasons of safety or effectiveness and would be removed from the Orange Book.^[2]

That does not erase decades of trial data, prove that every historical use had an unfavorable benefit-risk balance, or mean a compounded product is automatically counterfeit. It does mean “FDA-approved Anavar” is not an accurate description of the current U.S. situation. Oxandrolone remains a Schedule III anabolic steroid, and it is prohibited at all times under the 2026 World Anti-Doping Code list.^[1][15]

A new 2026 observational multicenter burn analysis is useful for contemporary practice questions, but treatment selection was not randomized. It should update hypotheses about comparative outcomes, not overwrite the older randomized evidence or be read as a head-to-head enhancement trial.^[16]

Oxandrolone works as an anabolic drug. The human file includes acute muscle-protein synthesis, increased lean tissue, larger MRI muscle area, modest strength gains and clinically meaningful recovery outcomes in severe burns. Among performance-adjacent compounds, that is a serious evidence base.

“Mild” is still the wrong summary. The term confuses nonaromatization and a comparatively favorable reputation with whole-body safety. Trials document unfavorable lipid changes and loss of gains after discontinuation; labeling documents hepatic, reproductive and virilizing risks. Current U.S. approval status is also unambiguous after FDA’s October 2026 correction.

The most exciting unanswered question is narrower than internet lore: in healthy, resistance-trained adults under standardized training and nutrition, how much additional contractile muscle and performance would verified oxandrolone add, how much would persist after stopping, and what would the lipid, liver and endocrine price be? The existing biology makes that trial worth running. The existing risks make it worth running well.